Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.

[1]  P. Casali,et al.  Adaptive immune contexture at the tumour site and downmodulation of circulating myeloid-derived suppressor cells in the response of solitary fibrous tumour patients to anti-angiogenic therapy , 2014, British Journal of Cancer.

[2]  C. Fournier,et al.  Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO) , 2013, Investigational New Drugs.

[3]  C. Morosi,et al.  Dacarbazine in Solitary Fibrous Tumor: A Case Series Analysis and Preclinical Evidence vis-à-vis Temozolomide and Antiangiogenics , 2013, Clinical Cancer Research.

[4]  L. Mariani,et al.  Response to chemotherapy of solitary fibrous tumour: a retrospective study. , 2013, European journal of cancer.

[5]  N. Zaffaroni,et al.  Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models. , 2013, Biochemical pharmacology.

[6]  K. Pienta,et al.  Identification of recurrent NAB2-STAT6 gene fusions in solitary fibrous tumor by integrative sequencing , 2013, Nature Genetics.

[7]  C. Fletcher,et al.  WHO classification of tumours of soft tissue and bone , 2013 .

[8]  J. Blay,et al.  Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience , 2013, BMC Cancer.

[9]  A. D. Dei Tos,et al.  Sunitinib malate in solitary fibrous tumor (SFT). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  J. Blay,et al.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.

[11]  Robin L. Jones,et al.  Conventional anthracycline-based chemotherapy has limited efficacy in solitary fibrous tumour , 2012, Acta oncologica.

[12]  M. Bhasin,et al.  High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma , 2011, Journal of Translational Medicine.

[13]  A. Lazar,et al.  Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor , 2011, Cancer.

[14]  D. Zopf,et al.  Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity , 2011, International journal of cancer.

[15]  G. Alí,et al.  Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo. , 2011, Neoplasia.

[16]  T. Choueiri,et al.  Pazopanib: Clinical development of a potent anti-angiogenic drug. , 2011, Critical reviews in oncology/hematology.

[17]  A. Cesne,et al.  Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed Malignant Haemangioperyctoma /Solitary Fibrous Tumour , 2010, Investigational New Drugs.

[18]  Haesun Choi,et al.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  G. Tonon,et al.  The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma , 2006, Proceedings of the National Academy of Sciences.

[20]  F. Mertens,et al.  World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone , 2002 .